Start the New Year with an in vivo shuttle session on our syngeneic orthotopic glioblastoma mouse model

11 / 14 / 2018

To get the opportunity to cost-effectively assess your drug candidates in our well-suited immunocompetent syngeneic model, do not miss our new in vivo glioblastoma shuttle session by mid-January 2019, in which a cost part will be supported by Explicyte.

Our validated syngeneic glioma mouse model is based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring. Model features as well as responsiveness to standard Temozolomide (TMZ) and immune checkpoint inhibitors (ICI) such as anti-PD1 antibody, makes it highly adapted for chemotherapeutic and immunotherapeutic candidate efficacy testing, either as single agents and/or in combinatorial regimen.

Orthotopic syngeneic GL261 glioblastoma model is responsive to TMZ and PD-1 blockade.

Mice were OT inoculated with GL261-Luc2 glioma cells and then treated with either Vehicle, TMZ or anti-PD1 antibody. Bioluminescence imaging was performed at Days 4, 14, and 21 after tumor cell inoculation. Survival was monitored overtime.




Common experimental settings:

  • Model / Strain: GL261-Luc2 glioblastoma / C57BL/6 mice
  • Readouts: Tumor growth (Bioluminescence imaging) / Body weight / Survival
  • Standard reference(s): TMZ or 𝛂PD1 monoclonal antibody – to be discussed with the Sponsor